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Objective: Intratumoral vessel invasion of non–small cell lung cancer is a readily available tumor-related factor
that provides direct evidence of microscopic tumor invasion. We assessed the prognostic influence of intratumoral
vessel invasion and its ability to provide a differential prediction of prognosis for completely resected pathologic
stage I non–small cell lung cancer.
Methods: We analyzed 258 patients with non–small cell lung cancer who underwent complete resection between
January of 1996 and December of 2005 and were diagnosed with pathologic stage I disease. In addition to the
conventional staging factors, intratumoral vessel invasion in the primary lesion was histologically evaluated
by both hematoxylin-eosin and elastic staining. We examined the significance of intratumoral vessel invasion
in prognosis and compared the outcomes between patients with and without this factor with stage IA and IB dis-
ease, respectively.
Results: Intratumoral vessel invasion was found in 124 patients (48%). Five-year survival of patients with or
without intratumoral vessel invasion was 74% and 93%, respectively. On multivariate analysis, intratumoral ves-
sel invasion and pleural invasion were shown to be independent prognostic factors. Subgroup analyses suggested
that patients with pathologic-stage IA with intratumoral vessel invasion and patients with pathologic-stage IB
with both intratumoral vessel and pleural invasion had significantly worse prognosis than patients with the
same pathologic stage without these factors.
Conclusion: The current study indicated that intratumoral vessel invasion and pleural invasion are independent
prognostic factors. Intratumoral vessel invasion status can complement the size-dependent TNM staging system
in pathologic stage I non–small cell lung cancer.Surgical resection still remains the most effective therapy for
patients with non–small cell lung cancer (NSCLC) limited to
the lung, especially stage I disease. However, reported sur-
vival outcome for resected stage I NSCLC may not be
enough to be satisfied. According to several large studies,
5-year survivals in resected stage IA and IB disease were
67% to 89% and 57% to 75%, respectively.1-6 There is
some variation in the survival data in the literature. One of
the reasons for this variation is that stage I NSCLC includes
populations with a different grade of malignancy. It is im-
portant to identify prognostic factors that reflect a risk of
mortality more precisely to make a reasonable staging diag-
nosis and to determine the population who can benefit from
adjuvant therapy for stage I NSCLC.
Some prognostic factors have been proposed for patients
with NSCLC. We have routinely examined intratumoral ves-
sel invasion (IVI; the evidence of lymphatic vessel invasion
[LVI] or blood vessel invasion [BVI]) status in addition to
factors for conventional TNM staging. Evaluation of IVI sta-
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doi:10.1016/j.jtcvs.2008.07.007The Journal of Thoracic and Ctus is valuable for 2 reasons: 1) It provides direct microscopic
evidence of tumor invasiveness and aggressiveness. 2) It is
readily available and can be objectively classified compared
with other morphologic classifications, such as grade of dif-
ferentiation. The purpose of the current study was to examine
clinicopathologic factors, including IVI, in 258 patients who
were treated in a similar manner and to identify the readily
available factors that predict patients with a high risk of mor-
tality with pathologic (p-) stage I NSCLC.
PATIENTS AND METHODS
Between January of 1996 and December of 2005, 452 patients with
NSCLC consecutively underwent surgery at Okayama Red Cross General
Hospital. Of these patients, 258 were pathologically proven to have single
stage I disease. We retrospectively reviewed these 258 cases with regard
to patient characteristics, tumor pathologic findings, and follow-up status
to examine the prognostic factors of value in patients with p-stage I NSCLC.
All patients in this study cohort had a preoperative systemic workup that
consisted of enhanced computed tomography of the entire trunk, magnetic
resonance imaging of the brain, and bone scintigraphy, which proved that
they had no distant metastasis. Patients with multiple lung cancers were ex-
cluded. The tumors were resected with no pathologic evidence of residual
tumor at the surgical margin. Regional lymph nodes in the hilum and medi-
astinum were also resected. The majority of patients underwent lobectomy
or pneumonectomy for resection of the primary lesion. In cases of lesser
pulmonary resection (wedge resection or segmentectomy), segmental or
subsegmental nodes were pathologically evaluated by intraoperative fro-
zen-section examination and confirmed as negative. All excised specimens
were formalin-fixed and sliced at 10-mm intervals. Histopathologic exami-
nation was performed by the same pathologist (T.K.). Pathologic staging
was determined according to the International Union Against Cancerardiovascular Surgery c Volume 137, Number 2 429
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BAC ¼ bronchioloalveolar carcinoma
BVI ¼ blood vessel invasion
CEA ¼ carcinoembryonic antigen
IVI ¼ intratumoral vessel invasion
LVI ¼ lymphatic vessel invasion
NSCLC ¼ non–small cell lung cancer
p ¼ pathologic
TNM classification of malignant tumors.7 Histologic subtypes of lung can-
cer were determined according to World Health Organization classifica-
tion.8 None of the patients received postoperative chemotherapy or
radiotherapy. All patients were followed up every 6 months at our outpatient
clinic after surgery.
Variables for Prognostic Analyses
We adopted the following factors as variables for this retrospective prog-
nostic analysis: age, gender, tumor diameter, pathologic evidence of pleural
invasion and IVI, histologic subtypes, extent of resection, and preoperative
serum carcinoembryonic antigen (CEA) levels. Data were abstracted from
medical and laboratory records by the authors. Informed consent for use
of the clinical data was obtained preoperatively from the patients, and the
institutional review board of the Okayama Red Cross General Hospital
waived the need for approval of the study. Pleural and vessel invasion in
the primary lesion were evaluated by hematoxylin-eosin and elastic staining
(Elastica van Gieson stain). The presence of IVI was determined by identi-
fying conspicuous findings of intravascular cancer clusters surrounded by
an elastic layer at the maximum section of the primary lesion. Cases that
the pathologist considered as equivocal were classified as the absence
group. Preoperative serum CEA levels were assessed by enzyme-linked im-
munosorbent assay kits, with an upper limit of normal of 5.0 ng/mL.
Statistical Analyses
Two-category comparison was performed by Pearson’s chi-square test
for quantitative data, presupposing a normal distribution. Survival probabil-
ity was calculated by the Kaplan–Meier method. The prognostic value of the
above-mentioned individual variables was tested by the log-rank test in uni-
variate analyses. To determine independent prognostic factors, multivariate
analysis was conducted by the Cox proportional hazards model (Wald
stepwise backward elimination method). Patient death, regardless of cause,
was defined as the terminal event. T1 (p-stage IA) and T2 (IB) cases were
respectively classified as 2 subgroups according to the existence of IVI
(IVIþor IVI), and the difference between the survival curves for each group
was analyzed by the log-rank test. Differences were considered as clinically
significant at P<0.01. Calculations and statistical tests were performed us-
ing the Statistical Package for the Social Sciences (SPSS Inc, Chicago, Ill).
RESULTS
Clinicopathologic Characteristics
Patients’ clinicopathologic characteristics are shown in
Table 1. The study cohort included 166 men and 92 women,
with a mean age of 67 years (range: 39–89 years; standard
deviation: 9.8). Lobectomy or pneumonectomy was per-
formed in 243 patients (94%), and lesser pulmonary resec-
tion was performed in 15 patients (6%). Diagnosis of
p-stage IA (T1) disease was made in 176 patients (68%),
and diagnosis of p-stage IB (T2) was made in 82 patients430 The Journal of Thoracic and Cardiovascular Sur(32%). Seventy-five patients (29%) had a tumor greater
than 30 mm in diameter, and 36 patients (14%) had a tumor
with pathologically proven pleural invasion (p1 or p2).
There were 185 patients (72%) with adenocarcinoma and
73 patients (28%) with other histologic types. Of 185 pa-
tients with adenocarcinoma, 12 had a diagnosis of true bron-
chioloalveolar carcinoma (BAC). IVI was found in 124
patients (48%). Of these 124 lesions, LVI was found in
114 patients, and BVI was found in 76 patients. The detec-
tion rates of LVI and BVI were 44% and 29%, respectively.
The preoperative serum CEA level was elevated in 49
patients (19%). Comparison of clinicopathologic features
between the absence and the presence of IVI showed that
IVI tended to be detected more frequently in those with
larger-sized tumors, squamous cell carcinoma, and elevated
CEA. A significant difference in the IVIþ rate was seen in
tumor diameter and histologic types (Table 2). The median
postoperative follow-up time was 56 months (range, 1–
136 months). There were 44 deaths during the follow-up
period, and 31 of these were cancer related. The overall 5-
year survival was 84% (p-stage IA, 89%; p-stage IB, 73%).
Univariate/Multivariate Prognostic Analyses
The results of univariate analysis are shown in Table 3.
Clinically significant survival predictors shown by
TABLE 1. Clinicopathologic characteristics
Factors No.(%)
Age
<70 y 143 (55)
70 y 115 (45)
Gender
Female 92 (36)
Male 166 (64)
p-stage
IA 176 (68)
IB 82 (32)
Tumor diameter (mm)
30 183 (71)
>30 75 (29)
Pleural invasion
Absence (p0) 222 (86)
Presence (p1 or p2) 36 (14)
IVI
Absence 134 (52)
Presence 124 (48)
Histologic types
Adenocarcinoma 185 (72)
Other 73 (28)
Extent of resection
Lobectomy or pneumonectomy 243 (94)
Wedge resection or segmentectomy 15 (6)
Preoperative serum CEA level
Normal 209 (81)
Elevated 49 (19)
IVI, Intratumoral vessel invasion; CEA, carcinoembryonic antigen; p, pathologic.gery c February 2009
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tumor diameter (30 vs>30 mm, P ¼ .0007), pleural inva-
sion (absence vs presence, P< .0001), and IVI (absence vs
presence, P< .0001). Survival curves of the IVIþand IVI
groups are shown in Figure 1. The 5-year survival of patients
with IVI and patients without IVI was 74% and 93%, re-
spectively. The 4 clinicopathologic factors of age, tumor
size, pleural invasion, and IVI, which were shown as impor-
tant predictors in univariate analysis, were included as cova-
riates for multivariate analysis 1. Of these factors, IVI was
shown to be a prognostic factor that retained an independent
level of significance (P ¼ .009), as was pleural invasion
(P ¼ .001) (Table 4). On multivariate analysis 2, the tumor
diameter was stratified into 3 categories (20,>20 and30,
>30) based on the proposed staging system (dividing T1 
30 into T1a  20 and T1b>20). On this setting, the prog-
nostic influence of IVI decreased but was marginally signif-
icant (P ¼ .032, hazard ratio 2.3; 95% confidence interval,
1.1–5.0) (Table 5).
Subgroup Survival Analyses
Survival curves of subgroups stratified according to both
T factor (T1 or T2) and IVI (IVIþor IVI) are shown in Fig-
ure 2. The 5-year survival of each stratified group was as fol-
lows: T1/IVIgroup (n ¼ 114), 95%; T1/IVIþgroup (n ¼
62), 78%; T2/IVI group (n ¼ 20), 84%; T2/IVIþ group
(n ¼ 62), 69%. The difference in survival probability be-
tween IVI and IVIþ was clinically significant in the T1
(stage IA) group (P ¼ .001) but not in the T2 (stage IB)
group, although the IVIþ group had a tendency toward
a worse outcome. Difference in survival probability was
not important in the T1/IVIþversus T2/IVI (P ¼ .49) and
T1/IVIþ versus T2/IVIþ (P ¼ .38) groups. An additional
subgroup analysis focused on the p-stage IB group revealed
that patients who had the tumor with both IVI and pleural
TABLE 2. Relationship between intratumoral vessel invasion and
other clinicopathologic factors
IVI Positive rate
(%)Factors Absence Presence P value
Tumor diameter (mm)
20 (n ¼ 122) 88 34 28 <.001
>20, 30 (n ¼ 61) 24 37 61
>30 (n ¼ 75) 22 53 71
Histologic type
Adenocarcinoma
(n ¼ 185)
108 77 42 .003
Squamous cell
carcinoma (n ¼ 50)
16 34 68
Other (n ¼ 23) 10 13 57
Preoperative serum CEA
Normal (n ¼ 209) 117 92 44 .011
Elevated (n ¼ 49) 17 32 65
IVI, Intratumoral vessel invasion; CEA, carcinoembryonic antigen.The Journal of Thoracic and Cinvasion (5-year survival, 43%) showed more unfavorable
prognosis than other patients with p-stage IB (P ¼ .007)
(Figure 3).
DISCUSSION
We confirmed IVI (LVI or BVI) and pleural invasion as
independent prognostic factors in resected p-stage I NSCLC,
and the additional subgroup analyses suggested that patients
TABLE 3. Univariate prognostic analysis
Variable 5-y survival (%) P value
Age
<70 y 89 .0042
70 y 77
Gender
Female 94 .019
Male 79
Tumor diameter (mm)
30 88 .0007
>30 74
Pleural invasion
Absence 89 <.0001
Presence 51
Histologic types
Adenocarcinoma 87 .011
Other 76
IVI
Absence 93 <.0001
Presence 74
Extent of resection
Lobectomy or pneumonectomy 83 .39
Wedge resection or segmentectomy 93
Preoperative serum CEA level
Normal 86 .020
Elevated 75
IVI, Intratumoral vessel invasion; CEA, carcinoembryonic antigen.
FIGURE 1. Kaplan–Meier survival curve for patients with p-stage I
NSCLC, stratified according to IVI. OS, Overall survival; IVI, intratumoral
vessel invasion.ardiovascular Surgery c Volume 137, Number 2 431
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both IVI and pleural invasion had worse prognosis than those
with the same p-stage without these factors. Although the
present study was retrospective and relatively small scale,
the analyzed patients received a similar quality of treatment
with an overall 5-year survival of 84%, which was reason-
able for an outcome of p-stage I disease. All operations
were performed by the same surgeon, and all specimens
were pathologically evaluated by the same single pathologist
throughout the study period. Even in patients with IVI
(74%), our 5-year survival data show much better results
than the data reported by Mountain4 for stage IA (67%)
and stage IB (57%) disease, on which the current TNM stag-
ing system is based. This survival discrepancy may be be-
cause more patients with cancer relapse in our series
received chemotherapy with the new generation of agents.
Our results can be applicable to North American and Euro-
pean patients only if the pathologic staging for each case is
sufficiently reliable.
Although the pathologic TNM staging system has been
considered to have an impact on survival in NSCLC, prob-
lems such as overlapping prognosis for patients with differ-
ent tumor stages and heterogeneous prognosis for patients
with the same tumor stage have been pointed out.2,6 These
problems need to be resolved to provide reasonable adjuvant
treatment or follow-up care for each patient with differing
risk of relapse or tumor death. Several retrospective studies
have examined the prognostic effect of the clinicopathologic
factors to identify patients with a different prognosis at each
stage or in some stratified groups. IVI has been shown to be
a strong independent predictor for p-stage I disease in most
studies that adopted this factor as a variable for analyses,9-14
TABLE 4. Multivariate prognostic analysis 1
Covariates Hazard ratio (95% CI) P value (Wald test)
Age
<70 vs 70 y 2.3 (1.2–4.4) .011
Tumor diameter (mm)
30 vs>30 1.6 (0.9–3.1) .12
Pleural invasion
absence vs presence 3.1 (1.6–6.1) .001
IVI
Absence vs presence 2.7 (1.3–5.8) .009
IVI, Intratumoral vessel invasion; CI, confidence interval.
TABLE 5. Multivariate prognostic analysis 2
Covariates Hazard ratio (95% CI) P value
Tumor diameter (mm)
20 vs>20, 30 2.3 (1.0–5.6) .054
20 vs>30 3.2 (1.4–7.3) .005
Pleural invasion
Absence vs presence 2.7 (1.4–5.2) .003
IVI
Absence vs presence 2.3 (1.1–5.0) .032
IVI, Intratumoral vessel invasion; CI, confidence interval.432 The Journal of Thoracic and Cardiovascular Surwith few exceptions.15,16 Both the current and previous stud-
ies suggest that IVI status can provide a differential predic-
tion of prognosis for patients with resected p-stage I disease.
The extent that elastic staining contributes to the detection
of IVI is not known. However, the value of elastic staining
can be inferred by referring to past literature in which IVI
was evaluated. The detection rates of LVI and BVI in p-stage
I without the elastic staining method were 0% to 3% and
11% to 16%, respectively.10,11 In contrast, the detection
rates of LVI and BVI with the elastic staining method
were 40% to 52% and 27% to 56%, respectively.9,12,17
The reported detection rate of IVI was higher in the studies
in which IVI was evaluated by elastic staining. This indi-
cates that elastic staining enables pathologists to more
precisely detect IVI. In addition, elastic staining is also help-
ful to identify visceral pleural invasion. Taube and col-
leagues18 reported that elastic staining resulted in the
change of tumor stage from IA to IB in 19% of patients
FIGURE 2. Kaplan–Meier survival curve for patients with p-stage I
NSCLC, stratified according to pathologic T factor and IVI. IVI, Intratu-
moral vessel invasion.
FIGURE 3. Kaplan–Meier survival curve for patients with p-stage IB dis-
ease, stratified according to IVI and pleural invasion. OS, Overall survival.
IVI, Intratumoral vessel invasion.gery c February 2009
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means of hematoxylin-eosin staining. This supports the val-
idity of using elastic staining for the histopathologic evalua-
tion of lung cancer specimens.
In most previous studies regarding tumor vessel invasion,
BVI and LVI were treated separately. However, we doubt
the importance of the separation between LVI and BVI.
There is some variation in the reported detection rate of
LVI and BVI for p-stage I NSCLC (LVI: 3%–50%; BVI:
11%–44%).9,10,12,13,15,16 Pathologists usually differentiate
blood vessels from lymphatic vessels according to the evi-
dence of blood cells in endothelium-lined channels, and dif-
ferentiation between them can be subjective, especially in
capillary areas. There is some ambiguity in the differentia-
tion between LVI and BVI. We used hematoxylin-eosin
and Elastica van Gieson stain for the evaluation. These stain-
ing methods were reliable for the detection of tumor cells in
vessels, although the ability to differentiate between LVI
and BVI was limited. We think that the IVI factor (grouping
together LVI and BVI) is readily available and can be objec-
tively classified (positive or negative).
Among the tumor factors, the tumor diameter in the max-
imum dimension is a valuable and readily available prognos-
tic factor based on gross anatomic findings. The sixth edition
of the International Union Against Cancer TNM staging
system adopted a diameter of 30 mm for the threshold of stra-
tification between T1 and T2. To improve the ability to pro-
vide a differential prognosis, some new thresholds of size
stratification (eg, 20 and 50 mm) have been proposed.19-21
However, clinicians sometimes encounter patients who
have a worse prognosis than they expect, based on tumor
size, as well as patients who have a better prognosis. The
current study and some previous studies have shown no sig-
nificance of tumor size for prognosis in resected p-stage I
NSCLC by multivariate analysis.9,13,22 One of the reasons
for the discrepancy between size classification and prognosis
is the existence of cases with some discrepancy between
tumor size and invasiveness. For adenocarcinoma, an in-
creasing number of tumors with a component of BAC
have recently been detected. The BAC component involves
neither stroma nor vessels, and patients with a large BAC
component have been known to have a good clinical out-
come.23 Differences in the proportion of the BAC compo-
nent can cause size-independent prognosis in patients with
adenocarcinoma. IVI can act as a prognostic factor in pa-
tients whose prognosis cannot be precisely predicted on
the basis of tumor size. In the next revision, the proposed
TNM staging system for lung cancer has created the T1a
descriptor for tumors 20 mm or less and the T1b descriptor
for tumors more than 20 mm to 30 mm or less. Although the
proposed size classification may predict tumor invasiveness
and prognosis better than the current system, we think the
IVI factor complements the staging system even in the pro-
posed staging setting according to our additional multivari-The Journal of Thoracic and Cate analysis (Table 5). We think that IVI status directly
indicates microscopic tumor progression. Prognostic predic-
tion using IVI is applicable to any tumors regardless of his-
tology and complements the present size-dependent TNM
staging system.
In the subgroup analysis of the current study, a survival
difference between the IVIþ and IVIgroups was found in
patients with stage IA (T1), but not in patients with stage
IB (T2). IVI is an especially strong predictor in the stage
IA group. Five-year survival of the patients with p-stage
IA with IVI was 78%, and no significant survival advantage
was found compared with patients with p-stage IB. There
was no clinical difference in the p-stage IB group with
IVI, perhaps because pleural invasion had an influence on
the survival data. Pleural invasion status is well recognized
as a strong prognostic factor.9,10,15,22,24,25 Our study also
confirmed pleural invasion as an independent predictor. Al-
though the stage IB group could not be classified into groups
with obviously different prognosis by IVI only, we found
a worse prognosis in patients with stage IB with both IVI
and pleural invasion than in patients without these factors.
The coexistence of IVI and pleural invasion is considered
to predict a poor prognosis in patients with stage IB.
Although the survival benefit of adjuvant therapy for re-
sected NSCLC has been expected in some trials,26,27 it is,
so far, controversial with regard to stage I disease. The latest
report of the Cancer and Leukemia Group B protocol 9633
trial revealed no significant overall 5-year survival for adju-
vant chemotherapy with carboplatin and paclitaxel in stage
IB disease.28 However, there are some problematic points
for the Cancer and Leukemia Group B protocol 9633 trial,
such as a heterogeneous population of the study cohort.29
Studies on the survival benefit of adjuvant therapy in some
subsets of patients should be conducted on the premise
that patients are classified using a reasonable staging system.
Clinical trials of adjuvant therapy for a well-selected popu-
lation with stage I disease and poor prognosis are needed.
IVI should be considered as one of the tumor-related factors
in patient selection for future trials of adjuvant therapy. We
diagnosed stage IA in patients with an obviously poor prog-
nosis using stratification by IVI. Even in patients with stage
IA, there may be some subsets of patients who benefit from
adjuvant chemotherapy, although adjuvant therapy for
patients with stage IA is not recommended at present.14
CONCLUSIONS
IVI status and pleural invasion were found to be indepen-
dent prognostic factors in resected p-stage I NSCLC. Poor
prognosis was observed in patients with p-stage IA with
IVI and patients with p-stage IB with both IVI and pleural
invasion. Prospective studies that examine the benefit of
adjuvant chemotherapy for patients with p-stage I with IVI
and pleural invasion are warranted.ardiovascular Surgery c Volume 137, Number 2 433
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